ICOTYDE Approval Adds New Growth Angle To Johnson & Johnson Valuation Story [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Johnson & Johnson (NYSE:JNJ) has received U.S. FDA approval for ICOTYDE, an oral IL-23 receptor inhibitor for moderate-to-severe plaque psoriasis. ICOTYDE is the first targeted oral IL-23 inhibitor and offers an alternative to injectable biologics for eligible adult and adolescent patients. The therapy is supported by Phase 3 efficacy and safety data and is part of a broader clinical program in psoriatic arthritis and inflammatory bowel diseases. For investors watching NYSE:JNJ, ICOTYDE adds a new asset to the company's immunology portfolio at a time when autoimmune disease treatments are a focus for large healthcare groups. Johnson & Johnson is aiming to address patients who cycle through topical therapies and may prefer an oral option instead of injections. The broader clinical program in psoriatic arthritis and inflammatory bowel dis
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Origin Materials and HP Embalagens enter PET cap distribution deal [Yahoo! Finance]Yahoo! Finance
- Barclays Sees Continued Strength in Johnson & Johnson (JNJ) Pharma Business [Yahoo! Finance]Yahoo! Finance
- Contact Lenses and Solutions Market to Reach USD 38.09 Billion by 2032 Amid Rising Vision Care Demand and Technological Advancements, Reports Vyansa Intelligence [Yahoo! Finance]Yahoo! Finance
- GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer [Yahoo! Finance]Yahoo! Finance
- ABBV Stock Slides 5%: Is J&J's Icotyde a Threat to Skyrizi? [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 3/18/26 - Form 13F-HR/A
- 3/18/26 - Form 13F-HR/A
- 3/12/26 - Form 4
- JNJ's page on the SEC website